---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-421076"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-10-14T12:52:13+00:00"
generated_at: "2026-10-14T12:55:02.247664+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aptevo to present CD40-directed multispecific platform at SITC 2026, Nov 4-8 in Phoenix

## Summary
- Abstract 1060, "Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor," to be presented by Michelle Nelson, PhD, at SITC 2026 in Phoenix.
- Presentation covers Aptevo's broader CD40-directed multispecific portfolio, designed to combine innate and adaptive immune activation within the tumor microenvironment.
- Company says tumor-directed CD40-activating molecules localize immune activation at the tumor while seeking to limit systemic immune activation.
- CSO Mary Janatpour, PhD, cited the work as continued evolution of the multispecific platform targeting persistent solid-tumor challenges.
- Slides to be posted on Aptevo's website Publications page after the November 4-8, 2026 meeting; no clinical data or timelines disclosed.

## SEC filing metadata
- accession: 0001193125-26-421076
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-10-14T12:52:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526421076/0001193125-26-421076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526421076/apvo-20261014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-421076
- JSON: https://secwatch.observer/filing/0001193125-26-421076.json
- Plain text: https://secwatch.observer/filing/0001193125-26-421076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.